araag2/HINT huggingface dataset:
Clinical trial NCT03140657 (phase 2, status: completed)
Conditions: ankylosing spondylitis
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: nanocurcumin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willingness to cooperate

          -  Aged 22 to 50 years

          -  The diagnosis of ankylosing spondylitis by rheumatologist

          -  Patients with a BASDAI > 4 as having active disease.

          -  Disease duration 5-8 years

        Exclusion Criteria:

          -  Nutritional supplements and antioxidant alpha-lipoic acid a month before the study.

          -  Pregnancy and lactation

          -  History of diabetes and other chronic diseases

          -  History of other autoimmune diseases

          -  Occurrence of relapses during the study period

          -  Acceptance rate of less than 70% of supplements

          -  Unwillingness to continue to cooperate
Clinical trial NCT03147196 (phase 2, status: withdrawn)
Conditions: stage i prostate adenocarcinoma, stage ii prostate adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: bicalutamide, raloxifene hydrochloride
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical
             stage T1a-T2c and planned for radical prostatectomy

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Platelet count >= 50,000/mm^3

          -  Hemoglobin > 9.0 g/dL

          -  Creatinine =< 2.0 mg/dL

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
             Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active
             treatment and observation), participants must be willing to return to the consenting
             institution for follow-up

          -  Patients must also provide written consent for biospecimens collection on
             Institutional Review Board (IRB) 08-000980

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  History of myocardial infarction =< 6 months, or congestive heart failure requiring
             use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

          -  History of a venous thromboembolic event, cerebrovascular accident (CVA), hepatic
             impairment, or heart failure
Clinical trial NCT03161574 (phase 2, status: withdrawn)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: folfoxiri
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    no participants were recruited
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of adenocarcinoma of the rectum

          -  Age: 18-70years old

          -  Signed informed consent; able to comply with study and/or followup procedures

          -  Stage of the primary tumor may be determined by MRI as CRM positive

          -  Tumor amenable to curative resection

          -  Adequate bone marrow, hepatic and renal function as assessed by the following
             laboratory requirements conducted within 7 days of starting study treatment:

          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet
             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.

          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.

          -  Alkaline phosphatase limit ≤ 5x ULN.

          -  Amylase and lipase ≤ 1.5 x the ULN.

          -  Serum creatinine ≤ 1.5 x the ULN.

          -  No renal disease that would preclude study treatment or followup

          -  ECOG status: 0～1

        Exclusion Criteria:

          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.

          -  Less than 4 weeks since prior participation in any investigational drug study

          -  History of invasive rectal malignancy, regardless of disease free interval

          -  Uncontrolled hypertension

          -  Cardiovascular disease that would preclude study treatment or followup

          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper
             gastrointestinal tract bleeding

          -  Synchronous colon cancer

          -  Pregnant or nursing

          -  Other malignancy within the past 5 years except effectively treated squamous cell or
             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or
             carcinoma in situ of the colon or rectum

          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the
             investigator, would preclude study participation

          -  patients refused to signed informed consent.
Clinical trial NCT03178669 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: cobitolimod, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Established diagnosis of Ulcerative Colitis (UC)

          -  Moderately to severely active left sided UC assessed by central reading

          -  Current oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) use or a history of
             oral 5-ASA/SP use

          -  Current Glucocorticosteroids (GCS) use or history of GCS dependency, refractory, or
             intolerance

          -  Demonstrated an inadequate response, loss of response, or intolerance to at least one
             of the following agents:

               -  Immunomodulators

               -  Tumor Necrosis Factor alpha (TNF-α) inhibitors and/or anti-integrins

        Exclusion Criteria:

          -  Suspicion of differential diagnosis

          -  Acute fulminant UC and/or signs of systemic toxicity

          -  UC limited to the rectum (disease which extend <15 cm above the anal verge)

          -  History of malignancy

          -  History or presence of any clinically significant disorder

          -  Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors,
             anti-integrins or similar immunosuppressants and immunomodulators

          -  Treatment with rectal GCS, 5-ASA/SP or tacrolimus

          -  Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Serious active infection

          -  Gastrointestinal infections

          -  Currently receiving parenteral nutrition or blood transfusions

          -  Females who are lactating or have a positive serum pregnancy test

          -  Women of childbearing potential not using reliable contraceptive methods

          -  Concurrent participation in another clinical study

          -  Previous exposure to cobitolimod
Clinical trial NCT03185871 (phase 2, status: withdrawn)
Conditions: breast carcinoma
ICD codes: C4A.52, C44.511, C44.521, D05.00, D05.01, D05.02, D05.10
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have biopsy proven invasive breast carcinoma stages T1cN0 to T3N0,
             ER or PR positive with tumors greater than 1cm without lymph node spread.

          -  Participants must have a mammographic breast composition category (density) of c or d.

          -  Participants must be willing to participate and provide signed informed consent.

          -  Participants must have no immediate requirements for chemotherapy, radiotherapy or
             hormonal therapy.

          -  Participants must be willing to discontinue any use of NSAIDs like aspirin or
             ibuprofen until the tumor is removed

          -  Participants cannot be taking the following medications because of major
             pharmacokinetic interactions with celecoxib while being enrolled in the study:
             Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole,
             Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine,
             Ticlopidine, Tirofiban, Vilazodone and Warfarin.

          -  Participants should pass MRI screening questionnaire

        Exclusion Criteria:

          -  Prior history of cancer, neo-adjuvant chemotherapy and radiation therapy

          -  No daily NSAIDs intake within the past 4 weeks. Intermittent non-daily NSAIDs is
             allowed under PI discretion.

          -  Current or prior systemic use of corticosteroids in the past month.

          -  Participants with history of hypertension, congestive heart failure, edema, stroke or
             other cardiac disease or condition.

          -  Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism.

          -  Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction,
             sulfonamide allergy

          -  Participants who are currently pregnant

          -  Participants with known human immunodeficiency virus (HIV) infection, hepatitis B
             carrier state or with clinical evidence of hepatitis B.

          -  Participants who are not able to understand or provide written informed consent.

          -  Participants with standard contraindications to non-contrast MRI will be excluded,
             including claustrophobia and metallic implants incompatible with MRI.

          -  Participants whose girth exceeds the bore of the MRI scanner.

          -  Participants requiring conscious sedation for MR imaging.
Clinical trial NCT03191864 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: apt-1011, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female between ≥18 and ≤75 years of age at the time of informed consent

          -  Signed informed consent

          -  Evidence of EoE defined by ≥15 peak eosinophils per HPF as measured from proximal and
             distal biopsies

          -  Subject-reported history of ≥3 episodes of dysphagia in the 7 days prior to Screening

          -  7-day Global EoE Symptom Score >3 at baseline and at screening

          -  Willing and able to adhere to study-related treatment regimens, procedures, and visit
             schedule

        Exclusion Criteria:

          -  Have known contraindication, hypersensitivity, or intolerance to corticosteroids;

          -  Have any physical, mental, or social condition or history of illness or laboratory
             abnormality that in the Investigator's judgment might interfere with study procedures
             or the ability of the subject to adhere to and complete the study;

          -  Presence of oral or esophageal mucosal infection of any type;

          -  Have any mouth or dental condition that prevents normal eating;

          -  Have any condition affecting the esophageal mucosa or altering esophageal motility
             other than EoE;

          -  Use of systemic corticosteroids within 60 days prior to Screening, use of
             inhaled/swallowed corticosteroids within 30 days prior to Screening, or extended use
             of high-potency dermal topical corticosteroids within 30 days prior to Screening;

          -  Initiation of an elimination diet or elemental diet within 30 days before Screening
             (diet must remain stable after signing ICF);

          -  Morning serum cortisol level ≤5 μg/dL (138 nmol/L);

          -  Use of biologic immunomodulators in the 24 weeks prior to Screening;

          -  Use of calcineurin inhibitors or purine analogues, or potent cytochrome P450 (CYP) 3A4
             inhibitors in the 12 weeks prior to Screening;

          -  Have a contraindication to or factors that substantially increase the risk of EGD or
             esophageal biopsy or have narrowing of the esophagus that precludes EGD with a
             standard 9 mm endoscope;

          -  Have a history of an esophageal stricture requiring dilatation within the previous 12
             weeks prior to Screening;

          -  Have initiated, discontinued or changed dosage regimen of PPIs, H2 antagonists,
             antacids or antihistamines for any condition such as GERD or allergic rhinitis within
             4 weeks prior to qualifying endoscopy. These drugs must remain constant throughout the
             study.

          -  A serum cortisol level <18 μg/dL (497 nmol/L) at 60 minutes with adrenocorticotropic
             hormone (ACTH) stimulation test using 250 μg cosyntropin (i.e., a positive result on
             the ACTH stimulation test).
Clinical trial NCT03193047 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: bempedoic acid 180mg, evolocumab
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years or legal age of majority depending on regional law

          -  Fasting, calculated LDL-C at screening ≥160 mg/dL and following PCSK9i therapy ≥70
             mg/dL

          -  Men and nonpregnant, nonlactating women

        Exclusion Criteria:

          -  Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia

          -  Total fasting TG ≥500 mg/dL

          -  Renal dysfunction or a glomerulonephropathy; eGFR <30 mL/min/1.73 m2

          -  Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or
             cerebrovascular disease (CD)

          -  History of type 1 or type 2 diabetes

          -  Uncontrolled hypertension

          -  Uncontrolled hypothyroidism

          -  Liver disease or dysfunction

          -  Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)

          -  History of hematologic or coagulation disorders

          -  History of malignancy (except non-metastatic basal or squamous cell carcinoma of the
             skin and cervical carcinoma in situ)

          -  Unexplained creatine kinase (CK) >3 × ULN

          -  Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months
             prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib

          -  Pregnant or breast feeding, or planning to become pregnant during treatment and/ or
             within 30 days after the end of treatment
Clinical trial NCT03193398 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: btrx-246040 oral capsule(s), placebo oral capsule(s)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of MDD as defined by DSM-5 criteria and have had at least 1
             prior major depressive episode in the past 10 years

          -  Patients must present with a new current episode of MDD and the duration of the
             current episode must be at least 4 weeks but not longer than 18 months.

          -  At Visit 1 (screening) and Visit 2 (baseline), patients must have clinically
             significant depressive symptoms defined by tandem (investigator- and
             computer-administered) Montgomery-Asberg Depression Rating Scale (MADRS) total scores
             ≥ 26 with a difference of ≤ 7 points between the Investigator- and
             computer-administered MADRS total scores

          -  Patients must have a CGI-S score ≥ 4 at Visit 2 (baseline).

        Exclusion Criteria:

          -  Patients who present with any current DSM-5 disorder other than MDD which is the focus
             of treatment.

          -  Patients who are homicidal in the opinion of the Investigator or are at suicidal risk
             (any suicide attempts within 12 months prior to Visit 1 [screening] or any suicidal
             intent, including a plan, within 3 months prior to Visit 1 [screening]; C-SSRS answer
             of "YES" on item 4 or 5 [suicidal ideation]; Investigator- or computer-administered
             MADRS score of ≥ 5 on item 10 [suicidal thoughts]; by Investigator clinical
             evaluation).

          -  Patients cannot have any history of substance or alcohol use disorder within 12 months
             prior to Visit 1 (screening) per DSM-5 criteria

          -  Patients must not have a clinically significant comorbid disease.
Clinical trial NCT03193957 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: etanercept
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects are male or female aged 18-55 years at the time of signing the informed
             consent form.

        Exclusion Criteria:

          -  Have been treated previously with monoclonal antibody agent including any tumour
             necrosis factor inhibitor except SB4.
Clinical trial NCT03196375 (phase 2, status: terminated)
Conditions: motor neuron disease
ICD codes: G12.20, G12.24, G12.29
Drugs: flx-787-odt (orally disintegrating tablet), placebo odt
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented diagnosis of Motor Neuron Disease (MND) [including Amyotrophic Lateral
             Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy
             (PMA)]

          -  Expected survival > 6 months

          -  Weekly muscle cramping (defined as: a sustained muscle contraction that's most often
             painful and lasts seconds to minutes)

        Exclusion Criteria:

          -  Presence of major gastrointestinal disorders, such as inflammatory bowel disease,
             diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux
             disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or
             esophageal lesions/ulcers

          -  Presence of laryngospasm or significant swallowing problems

          -  Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube

          -  Unable or unwilling to discontinue medications for cramps and/or opiates

          -  Inability to tolerate a spicy sensation in the mouth or stomach

          -  Actively using illicit drugs or history of chronic substance abuse within the past
             year prior to screening, including abuse of alcohol

          -  Intention to change the current level of tobacco use or use of nicotine-containing
             products (i.e., new smokers or those actively trying to quit may not enrolled)

          -  Participated in a clinical study (except natural history studies without
             administration of an investigational product) within 30 days prior to screening
Clinical trial NCT03197870 (phase 2, status: completed)
Conditions: nonproliferative diabetic retinopathy
ICD codes: E10.3213, E10.3293, E10.3313, E10.3393, E10.3413, E10.3493, E11.3213
Drugs: akb-9778, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Adults 18 through 80 years of age (inclusive)

          -  Subjects with moderate to very severe NPDR (ETDRS Level 43 - 53 inclusive)

          -  No evidence of central involved DME

          -  ETDRS BCVA letter score ≥ 70 (Snellen 20/40 or better)

        Key Exclusion Criteria:

          -  Ocular disease other than DR that may cause substantial reduction in visual acuity,
             including iris neovascularization, retinal detachment, visually significant epiretinal
             membrane, vitreous hemorrhage or fibrosis, ocular inflammation (uveitis), other
             retinal inflammatory or infectious diseases

          -  Evidence of neovascularization on clinical examination or imaging

          -  Hemoglobin A1C (HbA1C) ≥ 12.0% at Screening

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation
Clinical trial NCT03201601 (phase 2/phase 3, status: completed)
Conditions: polycystic ovarian syndrome, infertility
ICD codes: E28.2, N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: d-chiro-inositol, myoinositol
SMILES: O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Being diagnosed with PCOS according to Rotterdam criteria.

          -  Being in in vitro fertilization treatment.

          -  Body mass index less than 30 kg/m2.

          -  Accept freely to participate in the study and sign the informed consent document.

        Exclusion Criteria:

          -  Contraindication to perform techniques of assisted reproduction or stimulation of
             ovulation.

          -  Advanced state of endometriosis (III or IV).

          -  Classified as poor responder in fertility treatment.

          -  Premature ovarian failure.

          -  Severe male factor (cryptozoospermia).

          -  Few expectations of compliance and/or collaboration.